John C. Byrd

158 papers receiving 8.9k citations

John C. Byrd's Hit Papers

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia 2014 · 479 citations
4790+8+16Years since publication200400600

Peers

John C. Byrd
Comparison fields: 5 of 122
  • Genetics 5.8k
  • Pathology and Forensic Medicine 4.4k
  • Immunology 2.8k
  • Hematology 1.2k
  • Oncology 1.9k
Replace Adrian Wiestner with:
Adrian Wiestner United States
Paolo Ghia Italy
Richard R. Furman United States
Myron S. Czuczman United States
John M. Pagel United States
Guillaume Cartron France
Jonathan E. Kolitz United States
Beatríz Bellosillo Spain
A.J. Grillo-López United States
Matthew S. Davids United States
John C. Byrd relative to Adrian Wiestner United States Adrian Wiestner's profile →
Citations per field
00.5×1.5×
Adrian Wiestner · 1×
Citations per year

Countries citing papers authored by John C. Byrd

Since Specialization
Citations

This map shows the geographic impact of John C. Byrd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John C. Byrd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John C. Byrd more than expected).

Fields of papers citing papers by John C. Byrd

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John C. Byrd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John C. Byrd. The network helps show where John C. Byrd may publish in the future.

Co-authors

The 25 scholars most cited alongside John C. Byrd, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with John C. Byrd Line = papers co-authored together John C. Byrd links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 160 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study
Hit paper breakdown →
2002741
2
ZAP-70 Compared with Immunoglobulin Heavy-Chain Gene Mutation Status as a Predictor of Disease Progression in Chronic Lymphocytic Leukemia
Hit paper breakdown →
2004684
3
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia
Hit paper breakdown →
2014479
4 2001434
5 2004313
6 2002307
7 1998249
8 2006234
9 2014205
10 2014170
11 2000167
12 2003159
13 2000157
14 2003150
15 2007144
16 1999134
17 2012130
18
Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population.
2002124
19 2002105
20 1996102

About John C. Byrd

John C. Byrd is a scholar working on Genetics, Pathology and Forensic Medicine, Immunology, Oncology and Molecular Biology, having authored 160 papers that have together received 9.2k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (120 papers), Lymphoma Diagnosis and Treatment (86 papers), Immunodeficiency and Autoimmune Disorders (37 papers), Monoclonal and Polyclonal Antibodies Research (18 papers), Acute Lymphoblastic Leukemia research (18 papers), Advanced Breast Cancer Therapies (11 papers), Viral-associated cancers and disorders (9 papers) and Chronic Myeloid Leukemia Treatments (8 papers). The work is most often cited by research in Genetics (5.8k citations), Pathology and Forensic Medicine (4.4k citations), Immunology (2.8k citations), Hematology (1.2k citations) and Oncology (1.9k citations). John C. Byrd has collaborated with scholars based in United States, United Kingdom and Australia. Frequent co-authors include Ian W. Flinn, Michael R. Grever, Michael J. Keating, Thomas J. Kipps, Thomas S. Lin, Neil E. Kay, David Lucas, Michael Pearson, Robin Howard and Jamie K. Waselenko. Their work appears in journals such as Blood, Journal of Clinical Oncology, British Journal of Haematology, Cancer and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact